“Our positive results in animals with ongoing disease raise the possibility that oral anti-CD3 antibodies might be an effective immunomodulatory therapy for SLE that could be easily and rapidly ...

Anti-CD3 monoclonal antibody treatment to inhibit activated T cells holds promise; however, adverse effects associated with cytokine release are common. Visilizumab—humanized and modified anti ...

By studying the effects of the nasal anti-CD3 in a mouse model of TBI, researchers found the spray could reduce damage to the central nervous system and behavioral deficits, suggesting a potential ...

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

Researchers at Mass General Brigham found that a nasal spray delivering anti-CD3 (Foralumab) reduces neuroinflammation, limits central nervous system damage and improves behavioral outcomes in mice ...

On February 25, 2025, Tiziana Life Sciences announced the nearing completion of a preclinical study for their nasal anti-CD3 treatment, foralumab, which could provide a novel solution for long COVID.

Tiziana was previously notified by Nasdaq on January 29, 2025 that it was not in compliance with the minimum bid-price listing rule (under Rule 5550 (a) (2)) because its common stock failed to meet ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ...

anti-CD3 monoclonal antibody, today announced that the CEO of Tiziana Life Sciences, Ivor Elrifi, will be presenting during a fireside chat at the 37th Annual ROTH Conference and host 1x1 investor ...